AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 27 - (NewsRx.com & NewsRx.net) -- Watson Pharmaceuticals, Inc., (WPI) announced the nationwide availability of a new screening technology in the quest for early detection of cervical cancer.
PapSure is an in-office, noninvasive, direct visual screening exam cleared by the U.S. Food and Drug Administration (FDA) for all women recommended for a pelvic exam and a pap smear. PapSure combines the results of a traditional pap smear and speculoscopy (a visual examination of the cervix) using Speculite, a disposable, chemiluminescent light for vaginal illumination, which helps physicians visually identify cervical abnormalities or lesions that are potentially cancerous.
"We are pleased to add PapSure and the Speculite technology to the products we offer to the women's healthcare practitioner," said Allen Chao, PhD, chairman and CEO, Watson Pharmaceuticals, Inc. "At Watson, we truly believe in the advantages of early detection of cervical cancer. When physicians have the ability to detect cervical cancer in its earliest stages, then they are able to begin appropriate treatment of the disease and ultimately save patients' lives," Chao said.
PapSure has been clinically tested for more than 10 years in 12,000 women at 50 study centers. Clinical studies demonstrate that PapSure more than doubles the sensitivity for detecting abnormalities in cervical cancer screening to 92% compared with just 41% for a pap smear alone. Although PapSure detected significantly more disease than the pap smear alone, the increase in sensitivity was accompanied by an expected decrease in specificity from 95- 80%. PapSure also has a 99.1% negative predictive value, meaning that if a woman's PapSure exam is negative, she has a less than 1% chance of having cervical abnormalities or potentially cancerous lesions.
"PapSure is a significant breakthrough in cervical cancer screening, because it greatly reduces false-negatives, which some clinical studies show are as high as 55% with the pap ...
Source: HighBeam Research, New technology improves detection rate in cervical cancer...